New! View global litigation for patent families

US20080311127A1 - Combination therapy for treating disease - Google Patents

Combination therapy for treating disease Download PDF

Info

Publication number
US20080311127A1
US20080311127A1 US11981713 US98171307A US2008311127A1 US 20080311127 A1 US20080311127 A1 US 20080311127A1 US 11981713 US11981713 US 11981713 US 98171307 A US98171307 A US 98171307A US 2008311127 A1 US2008311127 A1 US 2008311127A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
patient
antigen
cancer
invention
chemotherapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11981713
Inventor
Birgit C. Schultes
Christopher F. Nicodemus
Antoine A. Noujaim
Ragupathy Madiyalakan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AltaRex Medical Corp
Original Assignee
AltaRex Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303Liver or Pancreas
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069Reproductive system, e.g. ovaria, uterus, testes, prostate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Disclosed are methods for treating cancer comprising administering a xenotypic antibody and a chemotherapeutic drug to a patient suffering from cancer. Also disclosed is a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen present in the host serum, which antigen does not elicit an effective host immune response, comprising administering to the patient a chemotherapeutic drug and a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair, wherein an effective host immune response is elicited against a second epitope on the antigen.

Description

    RELATED APPLICATIONS
  • [0001]
    This application is a continuation of U.S. application Ser. No. 10/831,886, filed on Apr. 26, 2004, which is a continuation-in-part of U.S. application Ser. No. 09/871,339, filed on May 31, 2001, which is a continuation of U.S. application Ser. No. 08/913,290, filed on Mar. 20, 1998, now U.S. Pat. No. 6,241,985, which is a National Stage application of PCT application number PCT/IB96/00461, filed on May 15, 1996; each of which is hereby incorporated in its entirety by reference. International Application No. PCT/IB96/00461 was published under PCT Article 21(2) in English.
  • BACKGROUND OF THE INVENTION
  • [0002]
    1. Field of the Invention
  • [0003]
    The invention relates to immunology. More particularly the invention relates to the use of immunotherapy in combination with chemotherapy.
  • [0004]
    2. Summary of the Related Art
  • [0005]
    Despite the progress that modern medicine has made in treating cancer, cancer recurrence remains a concern. For a majority of cancers, typical treatment includes surgery followed by high doses of chemotherapy. A majority of these patients relapse and do not respond to other chemotherapeutic treatments. These patients then avail themselves to experimental or salvage treatments.
  • [0006]
    Current experimental regimens focus on mixing chemotherapies in an attempt to overcome resistance issues. Most of these treatments result in serious blood toxicities such as neutropenia, and thrombocytopenia. Other serious and frustrating symptoms to the patient include hair loss and nausea. Researchers are now looking at ways to enhance the immune system through less toxic means while still eliminating the cancer.
  • [0007]
    Many have turned to the use of chemotherapy in conjunction with antibody treatments. Many of these have also presented similar toxicities to the chemotherapy.
  • [0008]
    Thus, there remains a need to identify new treatments that not only treat the initial symptoms of a disease, but also alleviate and/or prevent recurrence of those symptoms.
  • SUMMARY OF THE INVENTION
  • [0009]
    In a first aspect the invention provides a method for treating cancer, comprising concurrently administering xenotypic monoclonal antibody and a chemotherapeutic drug to a patient suffering from cancer. Preferably the patient is human.
  • [0010]
    In a second aspect the invention provides a method for treating cancer, comprising surgical removal of the cancer, concurrent administration of a chemotherapeutic drug and a xenotypic monoclonal antibody in a dose equal to or less than 2 mg.
  • [0011]
    In a third aspect, the invention provides a method for treating cancer, comprising surgical removal of the cancer, administration of a xenotypic monoclonal antibody on weeks 1, 3, 5, 9, followed by concurrent administration of a chemotherapeutic drug and a xenotypic monoclonal antibody on week 12 in a dose equal to or less than 2 mg.
  • [0012]
    In a fourth aspect, the invention provides a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen, which antigen does not elicit an effective host immune response, comprising concurrently administering to the patient a chemotherapeutic drug and a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair, wherein a host immune response is elicited against a second epitope on the antigen.
  • [0013]
    In a fifth aspect, the invention provides a method for treating cancer, comprising concurrent administration of a chemotherapeutic drug, a binding agent, and an antigen.
  • [0014]
    In a sixth aspect, the invention provides a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen, which antigen does not elicit an effective host immune response, comprising concurrently administering to the patient a chemotherapeutic drug and a composition comprising a binding agent present in an amount of from 0.1 μg to 2 mg per kg of body weight of the host, and wherein the binding agent specifically binds to an epitope on the antigen and an effective host immune response is elicited against a second epitope on the antigen.
  • [0015]
    In a seventh aspect, the invention provides a method for treating cancer, comprising administering a xenotypic antibody and a chemotherapeutic drug to a patient suffering from cancer.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0016]
    FIG. 1 provides a table illustrating the results of three clinical studies where Alt-2 is administered concurrently with a chemotherapeutic drug.
  • [0017]
    FIG. 2 is a diagram showing a non-limiting embodiment of the invention.
  • [0018]
    FIG. 3 is a graph showing the difference in the numbers between Ab2 responders (white squares) (effective immune response) and Ab2 non-responders (black squares) (ineffective immune response) over time.
  • [0019]
    FIG. 4 is a table illustrating the different disease characteristics of Ab2 responders and Ab2 non-responders.
  • DETAILED DESCRIPTION
  • [0020]
    The present invention stems from the discovery that a combination of immunotherapy with traditional chemotherapy and/or radiotherapy alleviates and/or prevents the recurrence of cancer. The presence of a host anti-xenotypic antibody response in a patient will stimulate an immune response. The inventors have exploited this discovery to develop therapeutics containing binding agents useful in immunotherapy and chemotherapeutic or radiotherapeutic drugs, as well as methods for using these therapeutics. The patents and publications cited herein reflect the level of skill in this field and are hereby incorporated by reference in their entirety to the same extent as if each was specifically and individually indicated to be incorporated by reference.
  • [0021]
    Accordingly in one embodiment, the invention provides a method for treating cancer, comprising concurrently administering xenotypic monoclonal antibody and a chemotherapeutic drug to a patient suffering from cancer. In some embodiments of the invention, the binding by the xenotypic monoclonal antibody of a first epitope exposes a second distinct epitope on the antigen. In some embodiments of the invention, the xenotypic monoclonal antibody, when bound to the antigen, forms an immunogenic complex. Exemplary xenotypic monoclonal antibodies (“MAb”), preferably include IgG1 antibodies; chimeric monoclonal antibodies (“C-MAb”); humanized antibodies; genetically engineered monoclonal antibodies (“G-MAb”); fragments of monoclonal antibodies (including but not limited to “F(Ab)2”, “F(Ab)” and “Dab”); and single chains representing the reactive portion of monoclonal antibodies (“SC-MAb”). The binding agent may be labeled or unlabeled.
  • [0022]
    Where the patient is human, preferred xenotypic monoclonal antibodies include, without limitation, murine monoclonal antibodies. Particularly preferred murine monoclonal antibodies include Alt-1 (murine IgG1, specifically binds to MUC-1; ATCC No. PTA-975; American Type Culture Collection, Manassas, Va.), Alt-2 (OvaRex® MAb B43.13, murine IgG1, specifically binds to CA125; ATCC No. PTA-1883), Alt3 (murine IgG3, specifically binds to CA19.9; ATCC No. PTA-2691), Alt-4 (murine IgM, specifically binds to CA19.9; ATCC No. PTA-2692), Alt-5 (murine IgG1, specifically binds to CA19.9; ATCC No. PTA-2690); and Alt-6 (murine IgG1, specifically binds to prostate specific antigen (PSA); ATCC No. HB12526).
  • [0023]
    In certain embodiments of the invention, the chemotherapeutic drug used is commercially available. Some non limiting examples include carboplatin, cisplatin, docetaxel, paclitaxel, doxorubicin, HCl liposome injection, topotecan, hydrochloride, gemcitabine, cyclophosphamide, and etoposide or any combination thereof.
  • [0024]
    In preferred embodiments the chemotherapeutic drug is administered within a week before or after the murine monoclonal antibody.
  • [0025]
    Chemotherapeutic agents of the invention include chemotherapeutic drugs commercially available. Merely to illustrate, the chemotherapeutic can be an inhibitor of chromatin function, a topoisomerase inhibitor, a microtubule inhibiting drug, a DNA damaging agent, an antimetabolite (such as folate antagonists, pyrimidine analogs, purine analogs, and sugar-modified analogs), a DNA synthesis inhibitor, a DNA interactive agent (such as an intercalating agent), and/or a DNA repair inhibitor.
  • [0026]
    Chemotherapeutic agents may be categorized by their mechanism of action into, for example, the following groups: anti-metabolites/anti-cancer agents, such as pyrimidine analogs (5-fluorouracil, floxuridine, capecitabine, gemcitabine and cytarabine) and purine analogs, folate antagonists and related inhibitors (mercaptopurine, thioguanine, pentostatin and 2-chlorodeoxyadenosine (cladribine)); antiproliferative/antimitotic agents including natural products such as vinca alkaloids (vinblastine, vincristine, and vinorelbine), microtubule disruptors such as taxane (paclitaxel, docetaxel), vincristin, vinblastin, nocodazole, epothilones and navelbine, epidipodophyllotoxins (etoposide, teniposide), DNA damaging agents (actinomycin, amsacrine, anthracyclines, bleomycin, busulfan, camptothecin, carboplatin, chlorambucil, cisplatin, cyclophosphamide, cytoxan, dactinomycin, daunorubicin, doxorubicin, epirubicin, hexamethylmelamineoxaliplatin, iphosphamide, melphalan, merchlorehtamine, mitomycin, mitoxantrone, nitrosourea, plicamycin, procarbazine, taxol, taxotere, teniposide, triethylenethiophosphoramide and etoposide (VP16)); antibiotics such as dactinomycin (actinomycin D), daunorubicin, doxorubicin (adriamycin), idarubicin, anthracyclines, mitoxantrone, bleomycins, plicamycin (mithramycin) and mitomycin; enzymes (L-asparaginase which systemically metabolizes L-asparagine and deprives cells which do not have the capacity to synthesize their own asparagine); antiplatelet agents; antiproliferative/antimitotic alkylating agents such as nitrogen mustards (mechlorethamine, cyclophosphamide and analogs, melphalan, chlorambucil), ethylenimines and methylmelamines (hexamethylmelamine and thiotepa), alkyl sulfonates-busulfan, nitrosoureas (carmustine (BCNU) and analogs, streptozocin), trazenes—dacarbazinine (DTIC); antiproliferative/antimitotic antimetabolites such as folic acid analogs (methotrexate); platinum coordination complexes (cisplatin, carboplatin), procarbazine, hydroxyurea, mitotane, aminoglutethimide; hormones, hormone analogs (estrogen, tamoxifen, goserelin, bicalutamide, nilutamide) and aromatase inhibitors (letrozole, anastrozole); anticoagulants (heparin, synthetic heparin salts and other inhibitors of thrombin); fibrinolytic agents (such as tissue plasminogen activator, streptokinase and urokinase), aspirin, dipyridamole, ticlopidine, clopidogrel, abciximab; antimigratory agents; antisecretory agents (breveldin); immunosuppressives (cyclosporine, tacrolimus (FK-506), sirolimus (rapamycin), azathioprine, mycophenolate mofetil); anti-angiogenic compounds (TNP-470, genistein) and growth factor inhibitors (vascular endothelial growth factor (VEGF) inhibitors, fibroblast growth factor (FGF) inhibitors); angiotensin receptor blocker; nitric oxide donors; anti-sense oligonucleotides; antibodies (trastuzumab, rituximab); cell cycle inhibitors and differentiation inducers (tretinoin); mTOR inhibitors, topoisomerase inhibitors (doxorubicin (adriamycin), amsacrine, camptothecin, daunorubicin, dactinomycin, eniposide, epirubicin, etoposide, idarubicin, irinotecan (CPT-11) and mitoxantrone, topotecan, irinotecan), corticosteroids (cortisone, dexamethasone, hydrocortisone, methylpednisolone, prednisone, and prenisolone); growth factor signal transduction kinase inhibitors; mitochondrial dysfunction inducers, toxins such as Cholera toxin, ricin, Pseudomonas exotoxin, Bordetella pertussis adenylate cyclase toxin, or diphtheria toxin, and caspase activators; and chromatin disruptors. Preferred dosages of the chemotherapeutic agents are consistent with currently prescribed dosages.
  • [0027]
    The methods according to the invention are useful for providing a therapeutic benefit to patients suffering from cancer. As used herein, the term “cancer” is used to mean a condition in which a cell in a patient's body undergoes abnormal, uncontrolled proliferation. The abnormal cell may proliferate to form a solid tumor, or may proliferate to form a multitude of cells (e.g., leukemia). Note that because cancer is the abnormal, uncontrolled proliferation of a patient's cell, the term does not encompass the normal proliferation of a cell, such as a stem cell or a spermatocyte.
  • [0028]
    By “treating a patient suffering from cancer” is meant that the patient's symptoms are alleviated following treatment according to the invention. In one non-limiting example, a patient suffering from a highly metastatic cancer (e.g., breast cancer) is treated where additional metastasis either do not occur, or are reduced in number as compared to a patient who does not receive treatment. In another non-limiting example, a patient is treated where the patient's solid cancer either becomes reduced in size or does not increase in size as compared to a patient who does not receive treatment. In yet another non-limiting example, the number of cancer cells (e.g., leukemia cells) in a treated patient either does not increase or is reduced as compared to the number of cancer cells in a patient who does not receive treatment. In preferred embodiments the patient is human.
  • [0029]
    It will be appreciated that a “patient suffering from cancer” of the invention may express the mutant protein and not yet be symptomatic for the disease. For example, where the cancer is colon cancer (which is associated with the mutant K-ras protein), a patient with a mutant K-ras protein in some cells of the colon is a patient according to the invention even though that patient may not yet be symptomatic for colon cancer. “Associated with a mutant protein” means signs or symptoms of illness in a majority of patients are present when the mutant protein is present in the patient's body, but in which signs or symptoms of illness are absent when the mutant protein is absent from the patient's body. “Signs or symptoms of illness” are clinically recognized manifestations or indications of disease.
  • [0030]
    In one embodiment of the present invention, the patient in need of treatment is suffering from cancer of the prostate, ovaries, breast, stomach, lung, colon, and skin. In a preferred embodiment, the patient in need of treatment is a human.
  • [0031]
    Preferably, the therapeutic compositions of the invention further comprise a pharmaceutically acceptable carrier. By “pharmaceutically acceptable carrier” is meant carrier that is physiologically acceptable to the administered patient. One exemplary pharmaceutically acceptable carrier is physiological saline. Other pharmaceutically-acceptable carriers and their formulations are well-known and generally described in, for example, Remington's Pharmaceutical Sciences (18th Edition, ed. A. Gennaro, Mack Publishing Co., Easton, Pa., 1990).
  • [0032]
    “Administering” as used herein means providing the composition to the patient in a manner that results in the composition being inside the patient's body. Such an administration can be by any route including, without limitation, parenteral, sub-cutaneous, intradermal, intravenous, intra-arterial, intraperitoneal, and intramuscular.
  • [0033]
    Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms such as described below or by other conventional methods known to those of skill in the art.
  • [0034]
    Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
  • [0035]
    The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular composition employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
  • [0036]
    In a second aspect the invention provides a method for treating cancer, comprising surgery, administration of a chemotherapeutic drug, administration of a xenotypic monoclonal antibody in a dose equal to or less than 2 mg given by intravenous infusion over 20 minutes during weeks 1, 3, 5, 9, then every 8 weeks, followed by administration of a chemotherapeutic drug within 5 days of the administration of the binding agent.
  • [0037]
    In certain, non-limiting embodiments of the invention, the xenotypic antibody, e.g., Alt-2, is administered as a 2 mg dose dissolved in 50 mL saline and infused slowly preferably over approximately 20 minutes. If an allergic or other reaction occurs that may limit the completion of the dose, then a lower dose may be employed at that time or with subsequent treatments, so that the expected dose range would be 1-2 mg per treatment. Premedication with oral or intravenous dyphenhydramine (25 to 50 mg) is usually administered to lessen the risk of allergic reaction to the protein. The schedule used for combined Alt-2 and chemotherapy comprises administering Alt-2 at the dose above at weeks 1, 3, 5, 7, 9 with chemotherapy administered with Alt-2 on weeks 12 through 26. Administration of Alt-2 may be started after recovery from any required surgery that is done prior to the chemotherapy and then continued up to, and during, the chemotherapy treatment period. The chemotherapy can be given in 3-4 week cycles or other schedules according to the treating physician and common clinical practice. Chemotherapy may continue for up to six cycles followed by the xenotypic antibody administration every twelve weeks for up to two years.
  • [0038]
    In another aspect, the method provides for treating cancer comprising surgery, followed within seven days by administration of a xenotypic monoclonal antibody in a dose equal to or less than 2 mg given by intravenous infusion over 20 minutes during weeks 1, 3, 5, 9, then every 8 weeks with concurrent administration of a chemotherapeutic drug at week 3 and thereafter.
  • [0039]
    In another aspect of the invention, the murine antibody is administered at week 1 after completing standard surgery but has not yet begun chemotherapy. The murine antibody is administered in a dose equal to or less than 2 mg via a 20 minute intravenous infusion followed by a second treatment and concurrent administration of a chemotherapeutic drug on weeks 6 and beyond. “Concurrent Administration” means administration within a relatively short time period from each other. Preferably such time period is less than 2 weeks, more preferably less than 7 days, most preferably less than 1 day and could even be administered simultaneously.
  • [0040]
    The expected progression-free survival times may be measured in months to years, depending on prognostic factors including the number of relapses, stage of disease, and other factors. Overall survival is also measured in months to years. In the case of ovarian cancer, the addition of the xenotypic monoclonal antibody, Alt-2 is expected to increase the time to recurrence or progression, and may also prolong the survival time. Any improvement of 2 months or longer is usually considered to be clinically meaningful.
  • [0041]
    In one aspect, the invention provides a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen in present in the host's serum, which antigen does not elicit a host immune response, comprising administering to the patient a chemotherapeutic drug and a composition comprising a binding agent that specifically binds to a first epitope ton the antigen and allowing the binding agent to form a binding agent/antigen pair, wherein a host immune response is elicited against a second epitope on the antigen. Exemplary multi-epitopic antigens are described in and herein incorporated by reference in Nicodemus C. F. et al, Expert Rev. Vaccines 1(1): 34-48 (2002); Qi et al, Hybridoma and Hybridomics 20: 313-323 (2001); and Berlyn et al., Clin. Immunol. 101: 276-283, (2001).
  • [0042]
    A “binding agent”, as used herein, refers to one member of a binding pair, including an immunologic pair, e.g., a binding moiety that is capable of binding to an antigen, preferably a single epitope expressed on the antigen, such as a pre-determined tumor antigen. In some embodiments of the invention, the binding of a first single epitope exposes a second distinct epitope on the antigen. In one embodiment of the invention, the binding agent, when bound to the antigen, forms an immunogenic complex. Exemplary binding agents include, but are not limited to: antibodies, monoclonal antibodies (“MAb”), preferably IgG1 antibodies; chimeric monoclonal antibodies (“C-MAb”); humanized antibodies; genetically engineered monoclonal antibodies (“G-MAb”); fragments of monoclonal antibodies (including but not limited to “F(Ab)2”, “F(Ab)” and “Dab”); single chains representing the reactive portion of monoclonal antibodies (“SC-MAb”); antigen-binding peptides; tumor-binding peptides; a protein, including receptor proteins; peptide; polypeptide; glycoprotein; lipoprotein, or the like, e.g., growth factors; lymphokines and cytokines; enzymes, immune modulators; hormones, for example, somatostatin; any of the above joined to a molecule that mediates an effector function; and mimics or fragments of any of the above. The binding agent may be labeled or unlabeled.
  • [0043]
    Preferred binding agents of the invention are monoclonal antibodies. Where the patient is human, these xenotypic monoclonal antibodies include, without limitation, murine monoclonal antibodies. Particularly preferred murine monoclonal antibodies include Alt-1 (murine IgGl, specifically binds to MUC-1; ATCC No. PTA-975; American Type Culture Collection, Manassas, Va.), Alt-2 (OvaRex® MAb B43.13, murine IgG1, specifically binds to CA125; ATCC No. PTA-1883), Alt3 (murine IgG3, specifically binds to CA19.9; ATCC No. PTA-2691), Alt-4 (murine IgM, specifically binds to CA19.9; ATCC No. PTA-2692), Alt-5 (murine IgG1, specifically binds to CAI 9.9; ATCC No. PTA-2690); and Alt-6 (murine IgG1, specifically binds to prostate specific antigen (PSA); ATCC No. HB-12526).
  • [0044]
    A “multi-epitopic in vivo tumor antigen” is an antigen that present multiple epitopes on its surface. Some non-limiting examples of such antigens include CA 125, MUC-1, PSA, CAI 9.9, and TAG-72.
  • [0045]
    “Inducing a host immune response” means that the patient experiences alleviation or reduction of signs or symptoms of illness, and specifically includes, without limitation, prolongation of survival. In certain preferred embodiments of the methods according to the invention, a CD8+ IFN-γ producing T cell is activated to induce a cytotoxic T lymphocyte (CTL) immune response in the patient administered the murine monoclonal antibody. In certain embodiments of the methods according to the invention, a CD4+ IFN-γ producing T cell is activated to induce a helper T cell immune response in the patient administered with the composition. These activated CD4+ IFN-γ producing T cells (i.e., helper T cells) provide necessary immunological help (e.g. by release of cytokines) to induce and maintain not only CTL, but also a humoral immune response mediated by B cells. Thus, in certain embodiments of the methods according to the invention, a humoral response to the antigen is activated in the patient administered with the composition.
  • [0046]
    Activation of a CD8+ and/or CD4+ IFN-γ producing T cells means causing T cells that have the ability to produce IFN-γ to actually produce IFN-γ, or to increase their production of IFN-γ. “Induction of CTL” means causing potentially cytotoxic T lymphocytes to exhibit antigen specific cytotoxicity. “Antigen specific cytotoxicity” means cytotoxicity against a cell presenting an antigen that is associated with the antigen associated with the cancer that is greater than an antigen that is not associated with the cancer. “Cytotoxicity” refers to the ability of the cytotoxic T lymphocyte to kill the target cell. Preferably, such antigen-specific cytotoxicity is at least 3-fold, more preferably 10-fold greater, more preferably more than 100-fold greater than cytotoxicity against a cell not presenting the antigen not associated with the cancer.
  • [0047]
    In another aspect, the invention includes a method for treating cancer, comprising concurrent administration of a chemotherapeutic drug, a binding agent, and an antigen.
  • [0048]
    In a further aspect, the invention provides a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen, which antigen does not elicit an effective host immune response, comprising concurrently administering to the patient a chemotherapeutic drug and a composition comprising a binding agent present in an amount of from 0.1 μg to 2 mg per kg of body weight of the host, and wherein the binding agent specifically binds to an epitope on the antigen and an effective host immune response is elicited against a second epitope on the antigen.
  • EQUIVALENTS
  • [0049]
    Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
  • [0050]
    All of the above-cited references and publications are hereby incorporated by reference in their entireties.
  • [0051]
    The following example is intended to further illustrate certain particularly preferred embodiments of the invention and is not intended to limit the scope of the invention.
  • EXAMPLE I Clinical and Immunologic Outcomes of Patients with Recurrent Epithelial Ovarian Cancer (EOC) treated with B43.13 and Chemotherapy (Ct)-Interim immunology and clinical results from study OVA-Gy-12
  • [0052]
    Patients with recurrence after platinum therapy and a first surgery and were enrolled if they were candidates for secondary surgery and continued chemotherapy. Alt-2 was administered by 20-minute infusion in weeks 1, 3, 5, and 9 prior to initiation of chemotherapy, and then an option to continue every 8 weeks×2 doses concurrent with chemotherapy on weeks 12 and 26. Humoral immune responses, including HAMA, Ab2 and anti-CA 125 antibody, were assessed at baseline and serially. Using gamma-interferon ELISPOT assay, T cell responses were evaluated for activation by Alt-2, CA125, or autologous tumor.
  • [0053]
    20 patients were enrolled; median follow-up was 6 months ranging up to 2 years. Alt-2 was well tolerated and did not produce drug-related serious adverse reactions. In 14 of 19 (710/6) evaluable patients, robust treatment-emergent humoral responses were observed to the constant (HAMA) and variable region of the antibody (Ab2). To date, 5 of 8 (62.5%) patients tested demonstrated functionally active T cells, stimulated by CAI or by autologous tumor. T cell responses to Alt-2 were demonstrated in 4 patients. T cell responses were MHC class I and 11 restricted, indicating the activation of CTL (cytotoxic T lymphocytes) and T helper cells. Immune responses were commonly induced by wk 12 after 4 doses, and were generally maintained in patients continuing combined treatment with Alt-2 and chemotherapy. 75% are still alive and median survival has not been reached at 120 weeks.
  • CONCLUSIONS
  • [0054]
    Alt-2 is well tolerated and induces multiple antigen-specific immune responses, even when combined with chemotherapy. In advanced EOC, these data are among the first to demonstrate induction of tumor-specific T cells.

Claims (24)

  1. 1. A method for treating cancer, comprising concurrently administering a xenotypic monoclonal antibody and a chemotherapeutic drug to a patient suffering from cancer.
  2. 2. The method of claim 1, wherein the xenotypic monoclonal antibody is murine.
  3. 3. The method of claim 2, wherein the antibody is selected from Alt-1, Alt-2, Alt-3, Alt-4, Alt-5, and Alt-6.
  4. 4. The method of claim 1, wherein the patient is a human.
  5. 5. The method of claim 1, wherein the chemotherapeutic is administered within a week before the monoclonal antibody.
  6. 6. The method of claim 1, wherein the chemotherapeutic is administered within a week after the monoclonal antibody.
  7. 7. The method of claim 1, wherein the antibody is administered in a dose of less than or equal to 2 mg.
  8. 8. The method of claim 2, further comprising surgical removal of the cancer.
  9. 9. A method for treating cancer, comprising surgical removal of the cancer and concurrent administration of a chemotherapeutic drug and a xenotypic monoclonal antibody in a dose equal to or less than 2 mg.
  10. 10. (canceled)
  11. 11. The method of claim 9, wherein administration of the antibody comprises a 20 minute intravenous infusion.
  12. 12-13. (canceled)
  13. 14. The method of claim 11, wherein the chemotherapeutic drug is administered within seven days prior to or following the administration of the monoclonal antibody, and wherein the chemotherapeutic drug is administered every four weeks for six cycles.
  14. 15. The method of claim 14, further comprising the step of administering the xenotypic monoclonal antibody every twelve weeks for up to two years.
  15. 16. The method of claim 15, wherein the xenotypic monoclonal antibody and chemotherapeutic drug are administered at weeks 1, 4, and 8, followed by further administration of the chemotherapeutic drug alone at weeks 12 and 16, followed by concurrent administration of the chemotherapeutic drug and xenotypic monoclonal antibody at week 20.
  16. 17. The method of claim 9, wherein the concurrent administration of the xenotypic monoclonal antibody and the chemotherapeutic drug occurs at week 1, followed by administration of the chemotherapeutic drug at week 4, wherein the concurrent administration is repeated for six cycles and followed by administration of the xenotypic monoclonal antibody every twelve weeks for up to two years.
  17. 18. A method for treating cancer in a patient, comprising surgical removal of the cancer and administration of a xenotypic monoclonal antibody at weeks 1, 3, 5, 7 and 9 followed by concurrent administration of a chemotherapeutic drug and a xenotypic monoclonal antibody in a dose less than or equal to 2 mg at week 12.
  18. 19-21. (canceled)
  19. 22. A method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen, which antigen does not elicit an effective host immune response, comprising concurrently administering to the patient a chemotherapeutic drug and a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair, wherein a host immune response is elicited against a second epitope on the antigen.
  20. 23-29. (canceled)
  21. 30. A method for treating cancer, comprising concurrent administration of a chemotherapeutic drug, a binding agent, and an antigen.
  22. 31-36. (canceled)
  23. 37. A method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen, which antigen does not elicit an effective host immune response, comprising concurrently administering to the patient a chemotherapeutic drug and a composition comprising a binding agent present in an amount of from 0.1 μg to 2 mg per kg of body weight of the host, and wherein the binding agent specifically binds to an epitope on the antigen and an effective host immune response is elicited against a second epitope on the antigen.
  24. 38. A method for treating cancer, comprising administering a xenotypic antibody and a chemotherapeutic drug to a patient suffering from cancer.
US11981713 1996-05-15 2007-10-31 Combination therapy for treating disease Abandoned US20080311127A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US08913290 US6241985B1 (en) 1996-05-15 1996-05-15 Method and composition for reconforming multi-epitopic antigens to initiate an immune response
IBPCT/IB96/00461 1996-05-15
PCT/IB1996/000461 WO1997042973A1 (en) 1996-05-15 1996-05-15 Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US09871339 US20010036457A1 (en) 1996-05-15 2001-05-31 Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US10831886 US8038994B2 (en) 1996-05-15 2004-04-26 Combination therapy for treating disease
US11981713 US20080311127A1 (en) 1996-05-15 2007-10-31 Combination therapy for treating disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11981713 US20080311127A1 (en) 1996-05-15 2007-10-31 Combination therapy for treating disease

Publications (1)

Publication Number Publication Date
US20080311127A1 true true US20080311127A1 (en) 2008-12-18

Family

ID=46171074

Family Applications (7)

Application Number Title Priority Date Filing Date
US08913290 Expired - Lifetime US6241985B1 (en) 1996-05-15 1996-05-15 Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US08877511 Expired - Lifetime US6086873A (en) 1996-05-15 1997-06-17 Therapeutic composition and method of treatment
US09871339 Abandoned US20010036457A1 (en) 1996-05-15 2001-05-31 Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US11472808 Abandoned US20070036798A1 (en) 1996-05-15 2006-06-21 Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US11981644 Abandoned US20080206318A1 (en) 1996-05-15 2007-10-31 Therapeutic compositions that alter the immune response
US11981714 Abandoned US20080131443A1 (en) 1996-05-15 2007-10-31 Method and composition for reconforming multi-epitopic antigens to intiate an immune response
US11981713 Abandoned US20080311127A1 (en) 1996-05-15 2007-10-31 Combination therapy for treating disease

Family Applications Before (6)

Application Number Title Priority Date Filing Date
US08913290 Expired - Lifetime US6241985B1 (en) 1996-05-15 1996-05-15 Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US08877511 Expired - Lifetime US6086873A (en) 1996-05-15 1997-06-17 Therapeutic composition and method of treatment
US09871339 Abandoned US20010036457A1 (en) 1996-05-15 2001-05-31 Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US11472808 Abandoned US20070036798A1 (en) 1996-05-15 2006-06-21 Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US11981644 Abandoned US20080206318A1 (en) 1996-05-15 2007-10-31 Therapeutic compositions that alter the immune response
US11981714 Abandoned US20080131443A1 (en) 1996-05-15 2007-10-31 Method and composition for reconforming multi-epitopic antigens to intiate an immune response

Country Status (9)

Country Link
US (7) US6241985B1 (en)
EP (2) EP1297846A1 (en)
JP (1) JP3565351B2 (en)
KR (1) KR20020011137A (en)
CA (1) CA2253602A1 (en)
DE (2) DE69626423D1 (en)
DK (1) DK0910407T3 (en)
ES (1) ES2193240T3 (en)
WO (1) WO1997042973A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090291075A1 (en) * 2002-04-11 2009-11-26 Altarex Medical Corp. Binding agents and their use in targeting tumor cells
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK85193D0 (en) 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
EP1820514A3 (en) * 1998-06-15 2007-10-17 AltaRex Medical Corporation Therapeutic compositions that produce an immune response by altering the antigen
DE69626423D1 (en) * 1996-05-15 2003-04-03 Altarex Inc A method and composition for remodeling multi-epitopic antigens to the immune response initiate
US7318921B2 (en) * 1996-05-15 2008-01-15 Altarex Medical Corp. Therapeutic compositions that alter the immune response
US20080220012A1 (en) * 1996-05-15 2008-09-11 Ragupathy Madiyalakan Therapeutic Compositions that alter the immune response
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
WO2001012217A9 (en) * 1999-08-18 2002-06-27 Altarex Inc Therapeutic antibody against muc-1 antigen and methods for their use
US6716966B1 (en) 1999-08-18 2004-04-06 Altarex Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
GB0514967D0 (en) * 2001-03-21 2005-08-24 Altarex Inc Therapeutic compositions that alter the immune response
ES2293751B1 (en) * 2001-03-21 2009-03-16 Altarex Medical Corp. Therapeutic compositions that alter the immune response (alt-014pc).
WO2002084249A3 (en) * 2001-04-10 2003-07-03 Hideki Garren Therapeutic and diagnostic uses of antibody specificity profiles
CA2464947C (en) * 2001-10-26 2012-05-22 Altarex Medical Corp. Combination therapy for treating disease
US8025873B2 (en) * 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
DK2891666T3 (en) * 2002-10-16 2017-10-02 Purdue Pharma Lp Antibodies that bind cell-associated CA 125 / O722P, and methods of use thereof
WO2004035003A3 (en) * 2002-10-17 2005-01-13 Altarex Medical Corp Therapeutic adjuvant
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
WO2006099175A3 (en) * 2005-03-11 2006-12-14 Earl F Albone Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
WO2007016340A3 (en) * 2005-07-29 2007-06-21 Providence Health System Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response
CA2623329A1 (en) * 2005-10-13 2007-04-19 Virexx Medical Corp. Chimeric antigen containing hepatitis c virus polypeptide and fc fragment for eliciting an immune response
JP2007320969A (en) * 2007-09-10 2007-12-13 Altarex Medical Corp Method for reconstructing multiple epitope-containing antigen for causing immune response, and composition

Citations (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4740371A (en) * 1984-09-17 1988-04-26 International Institute Of Cellular And Molecular Pathology Treatment of allergy
US4879225A (en) * 1986-06-20 1989-11-07 Neorx Corporation Enhanced production of antibodies utilizing insolubilized immune complexes
US4940670A (en) * 1986-01-24 1990-07-10 Rhodes Buck A Method for compounding and testing patient specific monoclonal antibodies and monoclonal antibody fragments for in vivo use
US4950480A (en) * 1986-05-06 1990-08-21 Connaught Laboratories Limited Enhancement of antigen immunogenicity
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4997762A (en) * 1984-01-31 1991-03-05 Akzo N.V. Tumor associated monocoloal antibodies derived from human B-cell line
US5009888A (en) * 1987-04-13 1991-04-23 Genzyme Corporation Therapeutic enzyme-antibody complexes
US5013547A (en) * 1989-02-07 1991-05-07 Erbamont, Inc. Anticancer drug - antibody conjugates and method for preparing same
US5053224A (en) * 1983-11-07 1991-10-01 Hilary Koprowski Induction of antibody response to solid tumors with anti-idiotype antibodies
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
US5183657A (en) * 1988-03-11 1993-02-02 Celltech Limited Antibodies for use in antilymphocyte antibody therapy
US5194254A (en) * 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
US5240833A (en) * 1989-01-30 1993-08-31 The Biomembrane Institute Method for the production of monoclonal antibodies directed to tumor-associated gangliosides and fucogangliosides
US5308614A (en) * 1988-03-28 1994-05-03 The Biomembrane Institute Methods for the production of antibodies and induction of immune responses to tumor-associated gangliosides by immunization with ganglioside lactones
US5478556A (en) * 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor
US5512283A (en) * 1990-07-06 1996-04-30 Allergene, Inc. Methods for the selective suppression of an immune response to dust mite der Pi
US5518723A (en) * 1993-05-07 1996-05-21 Akzo Nobel N.V. HIV immunogenic complexes
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5532159A (en) * 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
US5583202A (en) * 1989-02-24 1996-12-10 The Regents Of The University Of California Antigenized antibodies and genes
US5591593A (en) * 1991-04-23 1997-01-07 Antisoma Limited Minimum recognition unit of a PEM mucin tandem repeat specific monoclonal antibody and detection method using same
US5652114A (en) * 1983-03-04 1997-07-29 Health Research Inc. Diagnostic immunoassay methods using monoclonal antibody F36/22 which is specific for human breast carcinoma cells
US5688657A (en) * 1988-03-31 1997-11-18 International Bio-Immune Systems, Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
US5725856A (en) * 1988-01-12 1998-03-10 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5807978A (en) * 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5997315A (en) * 1996-09-17 1999-12-07 Fujitsu Takamisawa Component Limited Connector and IC card connector
US6069830A (en) * 1998-01-17 2000-05-30 Lg Semicon Co., Ltd. Circuit and method for sensing memory cell having multiple threshold voltages
US6077519A (en) * 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
US6088613A (en) * 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US6140091A (en) * 1997-06-20 2000-10-31 Boston Biomedical Research Institute Anti-idiotype vaccines to elicit catalytic antibodies
US6320185B1 (en) * 1998-05-18 2001-11-20 Olympus Optical Co., Ltd. Image detection apparatus
US6421287B1 (en) * 1997-12-04 2002-07-16 Cypress Semiconductor Corp. Method for controlling experimental inventory

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865689A (en) * 1972-11-09 1975-02-11 Hoffmann La Roche Method of producing carcinoembryonic antigens
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5084396A (en) * 1986-06-20 1992-01-28 Neorx Corporation Enhanced production of antibodies utilizing insolubilized immune complexes
US4921790A (en) 1987-04-24 1990-05-01 Research Corporation Tumor specific assay for CA125 ovarian cancer antigen
EP0377657A1 (en) 1987-08-19 1990-07-18 Centocor, Inc. Human ovarian tumor-associated antigen specific for monoclonal antibody ov-tl3
US5140091A (en) * 1988-03-03 1992-08-18 Daicel Chemical Industries Ltd. Compositions of polyether compounds, epoxy compounds and processes for production thereof based on 4-vinylcyclohexene-1-oxide
US5128119A (en) 1989-06-12 1992-07-07 Immunomedics, Inc. Methods for technetium/rhenium labeling of f(ab1)2 fragments
DE69231586D1 (en) 1992-01-03 2001-01-04 Rhomed Inc Pharmaceutical applications on the basis of peptide-metal ions
US6248332B1 (en) * 1990-10-05 2001-06-19 Medarex, Inc. Targeted immunostimulation with bispecific reagents
US5976818A (en) * 1991-12-16 1999-11-02 The Board Of Trustees Of The University Of Arkansas Monoclonal antibodies which identify the glycoprotein carrying the CA 125 epitope
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
ES2144522T3 (en) * 1993-05-27 2000-06-16 Uwe Dr Med Wagner CA125 monoclonal anti-anti-idiotypic and pharmaceutical compositions containing them.
EP0800578B1 (en) * 1994-12-28 2003-04-16 University Of Kentucky Recombinant monoclonal anti-idiotype antibody 3h1 sequences relating to human carcinoembryonic antigen
DE19531226C1 (en) * 1995-08-24 1997-04-03 Immuno Ag Pharmaceutical compsn. for prevention or treatment of viral disease
DE69626423D1 (en) * 1996-05-15 2003-04-03 Altarex Inc A method and composition for remodeling multi-epitopic antigens to the immune response initiate
US7318921B2 (en) * 1996-05-15 2008-01-15 Altarex Medical Corp. Therapeutic compositions that alter the immune response

Patent Citations (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US5652114A (en) * 1983-03-04 1997-07-29 Health Research Inc. Diagnostic immunoassay methods using monoclonal antibody F36/22 which is specific for human breast carcinoma cells
US5053224A (en) * 1983-11-07 1991-10-01 Hilary Koprowski Induction of antibody response to solid tumors with anti-idiotype antibodies
US4997762A (en) * 1984-01-31 1991-03-05 Akzo N.V. Tumor associated monocoloal antibodies derived from human B-cell line
US4740371A (en) * 1984-09-17 1988-04-26 International Institute Of Cellular And Molecular Pathology Treatment of allergy
US4940670A (en) * 1986-01-24 1990-07-10 Rhodes Buck A Method for compounding and testing patient specific monoclonal antibodies and monoclonal antibody fragments for in vivo use
US5194254A (en) * 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
US4950480A (en) * 1986-05-06 1990-08-21 Connaught Laboratories Limited Enhancement of antigen immunogenicity
US4879225A (en) * 1986-06-20 1989-11-07 Neorx Corporation Enhanced production of antibodies utilizing insolubilized immune complexes
US5009888A (en) * 1987-04-13 1991-04-23 Genzyme Corporation Therapeutic enzyme-antibody complexes
US5725856A (en) * 1988-01-12 1998-03-10 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5183657A (en) * 1988-03-11 1993-02-02 Celltech Limited Antibodies for use in antilymphocyte antibody therapy
US5308614A (en) * 1988-03-28 1994-05-03 The Biomembrane Institute Methods for the production of antibodies and induction of immune responses to tumor-associated gangliosides by immunization with ganglioside lactones
US5389530A (en) * 1988-03-28 1995-02-14 The Biomembrane Institute Methods for the production of antibodies and induction of immune responses to tumor-associated ganagliosides by immunization with gangloiside lactones
US5500215A (en) * 1988-03-28 1996-03-19 The Biomembrane Institute Methods for the production of antibodies and induction of immune responses to tumor-associated gangliosides by immunization with ganglioside lactones
US5688657A (en) * 1988-03-31 1997-11-18 International Bio-Immune Systems, Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5240833A (en) * 1989-01-30 1993-08-31 The Biomembrane Institute Method for the production of monoclonal antibodies directed to tumor-associated gangliosides and fucogangliosides
US5013547A (en) * 1989-02-07 1991-05-07 Erbamont, Inc. Anticancer drug - antibody conjugates and method for preparing same
US5583202A (en) * 1989-02-24 1996-12-10 The Regents Of The University Of California Antigenized antibodies and genes
US6088613A (en) * 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
US5512283A (en) * 1990-07-06 1996-04-30 Allergene, Inc. Methods for the selective suppression of an immune response to dust mite der Pi
US5591593A (en) * 1991-04-23 1997-01-07 Antisoma Limited Minimum recognition unit of a PEM mucin tandem repeat specific monoclonal antibody and detection method using same
US6077519A (en) * 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5518723A (en) * 1993-05-07 1996-05-21 Akzo Nobel N.V. HIV immunogenic complexes
US5478556A (en) * 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor
US5532159A (en) * 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
US5807978A (en) * 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5997315A (en) * 1996-09-17 1999-12-07 Fujitsu Takamisawa Component Limited Connector and IC card connector
US6140091A (en) * 1997-06-20 2000-10-31 Boston Biomedical Research Institute Anti-idiotype vaccines to elicit catalytic antibodies
US6421287B1 (en) * 1997-12-04 2002-07-16 Cypress Semiconductor Corp. Method for controlling experimental inventory
US6069830A (en) * 1998-01-17 2000-05-30 Lg Semicon Co., Ltd. Circuit and method for sensing memory cell having multiple threshold voltages
US6320185B1 (en) * 1998-05-18 2001-11-20 Olympus Optical Co., Ltd. Image detection apparatus

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US20090291075A1 (en) * 2002-04-11 2009-11-26 Altarex Medical Corp. Binding agents and their use in targeting tumor cells

Also Published As

Publication number Publication date Type
JP3565351B2 (en) 2004-09-15 grant
EP0910407A1 (en) 1999-04-28 application
EP1297846A1 (en) 2003-04-02 application
US20080131443A1 (en) 2008-06-05 application
US20010036457A1 (en) 2001-11-01 application
EP0910407B1 (en) 2003-02-26 grant
US20080206318A1 (en) 2008-08-28 application
ES2193240T3 (en) 2003-11-01 grant
US6086873A (en) 2000-07-11 grant
WO1997042973A1 (en) 1997-11-20 application
KR20020011137A (en) 2002-02-07 application
DK0910407T3 (en) 2003-06-16 grant
DE69626423D1 (en) 2003-04-03 grant
CA2253602A1 (en) 1997-11-20 application
DE69626423T2 (en) 2004-03-18 grant
US20070036798A1 (en) 2007-02-15 application
JPH11509558A (en) 1999-08-24 application
US6241985B1 (en) 2001-06-05 grant

Similar Documents

Publication Publication Date Title
Brown et al. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon
Lu et al. Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential
Dillman Antibodies as cytotoxic therapy.
Kuan et al. EGF mutant receptor vIII as a molecular target in cancer therapy.
Stern et al. Overview of monoclonal antibodies in cancer therapy: present and promise
US20060057111A1 (en) Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
Lu et al. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors
US7960515B2 (en) Binding molecules to the human OX40 receptor
US20030157104A1 (en) Treatment of refractory human tumors with epidermal growth factor receptor antagonists
US20070071761A1 (en) Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody
US7318924B2 (en) Antibodies against cancer
WO2002055106A2 (en) Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
WO2009062690A1 (en) Axl antibodies
WO1992007466A1 (en) Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
US20030202973A1 (en) Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists
WO2008019378A1 (en) Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
US20080025913A1 (en) Novel Anti-Dc-Sign Antibodies
WO2001070268A1 (en) Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
US20130122020A1 (en) Antibodies specific for trop-2 and their uses
WO2003006059A1 (en) Vegfr-1 antibodies to treat breast cancer
US7097836B1 (en) Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody
Dillman Monoclonal antibody therapy for lymphoma
WO2008133851A1 (en) Methods and compositions for the treatment of prostate cancer
WO2008153237A1 (en) Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof
US20130323249A1 (en) Antigen Binding Proteins that Bind PD-L1